Summary

Some upcoming treatments for Alzheimer's Disease, particularly those of a preventative nature, rely upon participation in clinical research from individuals diagnosed with either Prodromal Alzheimer's Disease (pAD) or Minimal Cognitive Impairment (MCI) at risk of developing AD. Identifying these individuals paves the way for early intervention with the goal of completely slowing or halting the onset of Alzheimer's. Whilst this patient population remains functionally independent, without the challenges of recruiting those with severe memory impairment, these clinical trials can be difficult to recruit in part, due to biomarker eligibility requirements which may include PET imaging and/or cerebrospinal fluid assessments. Screening of subjects is therefore costly and time-consuming, with a significant screen fail rate.

Register to download

Tactics for Successful Patient Recruitment in Alzheimer's Clinical Studies